XWARSCP
Market cap98mUSD
Dec 23, Last price
148.80PLN
1D
4.20%
1Q
-8.94%
IPO
963.62%
Name
Scope Fluidics SA
Chart & Performance
P/E
—
P/S
786.08
EPS
—
Div Yield, %
57.51%
Shrs. gr., 5y
3.32%
Rev. gr., 5y
195.27%
Revenues
516k
+27.72%
Net income
-19m
L
CFO
-19m
L-32.32%
Dividend
Mar 24, 202385.57 PLN/sh
Profile
Scope Fluidics S.A., a biotechnology company, engages in the designing and developing projects based on microfluidic technologies in medical diagnostics and healthcare. It offers BacterOMIC, an antibiotic susceptibility testing. The company was founded in 2010 and is based in Warsaw, Poland.
Valuation
Title PLN in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 516 27.72% | 404 | |||||||
Cost of revenue | 1,888 | 872 | 5,755 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (1,372) | (468) | (5,755) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | 129 | 69,054 | 1,000 | ||||||
Tax Rate | |||||||||
NOPAT | (1,501) | (69,522) | (5,756) | ||||||
Net income | (18,785) -105.90% | 318,489 -6,388.04% | (5,065) | ||||||
Dividends | (233,258) | ||||||||
Dividend yield | 43.66% | ||||||||
Proceeds from repurchase of equity | 4 | 18,514 | |||||||
BB yield | 0.00% | -5.05% | |||||||
| Debt | |||||||||
Debt current | 873 | 571 | 357 | ||||||
Long-term debt | 3,945 | 4,339 | 14,624 | ||||||
Deferred revenue | 3,745 | 3,689 | 3,455 | ||||||
Other long-term liabilities | 8,956 | 2,660 | 12,655 | ||||||
Net debt | (82,871) | (327,343) | (3,267) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (19,057) | (28,158) | (22,190) | ||||||
CAPEX | (2,151) | (1,298) | (4,910) | ||||||
Cash from investing activities | (12,026) | 371,126 | (3,335) | ||||||
Cash from financing activities | (234,224) | (30,280) | 17,906 | ||||||
FCF | (1,505) | (52,527) | (26,172) | ||||||
| Balance | |||||||||
Cash | 87,193 | 331,598 | 18,089 | ||||||
Long term investments | 496 | 655 | 159 | ||||||
Excess cash | 87,663 | 332,233 | 18,248 | ||||||
Stockholders' equity | 9,459 | 261,502 | (41,904) | ||||||
Invested Capital | 86,581 | 80,275 | 86,066 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 2,726 | 2,699 | 2,686 | ||||||
Price | 196.00 -5.54% | 207.50 52.13% | 136.40 1.04% | ||||||
Market cap | 534,296 -4.59% | 559,985 52.83% | 366,398 5.82% | ||||||
EV | 451,425 | 232,642 | 363,131 | ||||||
EBITDA | (292) | 196 | (5,341) | ||||||
EV/EBITDA | 1,186.95 | ||||||||
Interest | 329 | 10,826 | 1,418 | ||||||
Interest/NOPBT | |||||||||